+Follow
Chidubem Thomas
No personal profile
12
Follow
1
Followers
0
Topic
0
Badge
Posts
Hot
Chidubem Thomas
09-18
Thanks for contacting me
Novo Nordisk Jumps 7% as Wegovy Pill Delivers 16.6% Weight Loss; Semaglutide Significantly Reduces Cardiovascular Risk
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4120588888192682","uuid":"4120588888192682","gmtCreate":1758187216533,"gmtModify":1758187273286,"name":"Chidubem Thomas","pinyin":"chidubemthomaschidubemthomas","introduction":"","introductionEn":null,"signature":"","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":12,"tweetSize":1,"questionSize":0,"limitLevel":999,"accountStatus":1,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"init","userBadges":[],"userBadgeCount":0,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":10,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":479904954815200,"gmtCreate":1758188456674,"gmtModify":1758189054969,"author":{"id":"4120588888192682","authorId":"4120588888192682","name":"Chidubem Thomas","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4120588888192682","authorIdStr":"4120588888192682"},"themes":[],"htmlText":"Thanks for contacting me ","listText":"Thanks for contacting me ","text":"Thanks for contacting me","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/479904954815200","repostId":"2568342652","repostType":2,"repost":{"id":"2568342652","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1758188259,"share":"https://ttm.financial/m/news/2568342652?lang=en_US&edition=fundamental","pubTime":"2025-09-18 17:37","market":"sh","language":"en","title":"Novo Nordisk Jumps 7% as Wegovy Pill Delivers 16.6% Weight Loss; Semaglutide Significantly Reduces Cardiovascular Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2568342652","media":"Dow Jones","summary":"Shares of $Novo Nordisk(NVO)$ continued to jump 7% in premarket trading.Novo's experimental daily Wegovy pill helped patients lose about as much weight as its weekly injection, according to data from...","content":"<html><head></head><body><p>Shares of <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> continued to jump 7% in premarket trading.</p><p>Novo's experimental daily Wegovy pill helped patients lose about as much weight as its weekly injection, according to data from a late-stage trial. Additionly, Novo Nordisk has announced the results of the REACH real-world study.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/be53cc818a2ab5a359d3e81ecb9ccbbd\" title=\"\" tg-width=\"840\" tg-height=\"621\"/></p><p>Results showed that if all patients adhered to treatment, they <strong>lost an average 16.6% of their weight,</strong> comparable with previous trial results of its once-weekly Wegovy jab, the company said late Wednesday.</p><p>The 64-week trial tested obese or overweight adults with a weight-related condition but without diabetes, and more than a third of those in the trial achieved weight loss of 20% or more, it said.</p><p>The study also found the pill improved cardiovascular risk factors, as well as the ability to be more active in daily life, while the safety and tolerability profile was consistent with the Wegovy jab.</p><p>Additionly, Novo Nordisk has announced the results of the REACH real-world study, which indicate that <strong>Ozempic (once-weekly injectable semaglutide) is associated with a 23% reduced risk of major adverse cardiovascular events, such as heart attack or stroke</strong>, compared to dulaglutide.</p><p>The study involved nearly 60,000 US Medicare patients aged 66 years or older with type 2 diabetes and atherosclerotic cardiovascular disease.</p><p>Additionally, Ozempic was linked to a 26% lower risk of death compared to dulaglutide. These findings, presented at the European Association for the Study of Diabetes (EASD) 2025 Annual Meeting in Vienna, Austria, are the first to directly compare the cardiovascular outcomes of these glucagon-like peptide 1 receptor agonist medications in a real-world setting. This study contributes to the understanding of the impact of these treatments on heart health in older populations at high risk.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk Jumps 7% as Wegovy Pill Delivers 16.6% Weight Loss; Semaglutide Significantly Reduces Cardiovascular Risk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk Jumps 7% as Wegovy Pill Delivers 16.6% Weight Loss; Semaglutide Significantly Reduces Cardiovascular Risk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-09-18 17:37</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Shares of <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> continued to jump 7% in premarket trading.</p><p>Novo's experimental daily Wegovy pill helped patients lose about as much weight as its weekly injection, according to data from a late-stage trial. Additionly, Novo Nordisk has announced the results of the REACH real-world study.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/be53cc818a2ab5a359d3e81ecb9ccbbd\" title=\"\" tg-width=\"840\" tg-height=\"621\"/></p><p>Results showed that if all patients adhered to treatment, they <strong>lost an average 16.6% of their weight,</strong> comparable with previous trial results of its once-weekly Wegovy jab, the company said late Wednesday.</p><p>The 64-week trial tested obese or overweight adults with a weight-related condition but without diabetes, and more than a third of those in the trial achieved weight loss of 20% or more, it said.</p><p>The study also found the pill improved cardiovascular risk factors, as well as the ability to be more active in daily life, while the safety and tolerability profile was consistent with the Wegovy jab.</p><p>Additionly, Novo Nordisk has announced the results of the REACH real-world study, which indicate that <strong>Ozempic (once-weekly injectable semaglutide) is associated with a 23% reduced risk of major adverse cardiovascular events, such as heart attack or stroke</strong>, compared to dulaglutide.</p><p>The study involved nearly 60,000 US Medicare patients aged 66 years or older with type 2 diabetes and atherosclerotic cardiovascular disease.</p><p>Additionally, Ozempic was linked to a 26% lower risk of death compared to dulaglutide. These findings, presented at the European Association for the Study of Diabetes (EASD) 2025 Annual Meeting in Vienna, Austria, are the first to directly compare the cardiovascular outcomes of these glucagon-like peptide 1 receptor agonist medications in a real-world setting. This study contributes to the understanding of the impact of these treatments on heart health in older populations at high risk.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4007":"制药","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4585":"ETF&股票定投概念","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4588":"碎股","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4599":"减肥药","NVO":"诺和诺德","BK4532":"文艺复兴科技持仓","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC"},"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2568342652","content_text":"Shares of Novo Nordisk continued to jump 7% in premarket trading.Novo's experimental daily Wegovy pill helped patients lose about as much weight as its weekly injection, according to data from a late-stage trial. Additionly, Novo Nordisk has announced the results of the REACH real-world study.Results showed that if all patients adhered to treatment, they lost an average 16.6% of their weight, comparable with previous trial results of its once-weekly Wegovy jab, the company said late Wednesday.The 64-week trial tested obese or overweight adults with a weight-related condition but without diabetes, and more than a third of those in the trial achieved weight loss of 20% or more, it said.The study also found the pill improved cardiovascular risk factors, as well as the ability to be more active in daily life, while the safety and tolerability profile was consistent with the Wegovy jab.Additionly, Novo Nordisk has announced the results of the REACH real-world study, which indicate that Ozempic (once-weekly injectable semaglutide) is associated with a 23% reduced risk of major adverse cardiovascular events, such as heart attack or stroke, compared to dulaglutide.The study involved nearly 60,000 US Medicare patients aged 66 years or older with type 2 diabetes and atherosclerotic cardiovascular disease.Additionally, Ozempic was linked to a 26% lower risk of death compared to dulaglutide. These findings, presented at the European Association for the Study of Diabetes (EASD) 2025 Annual Meeting in Vienna, Austria, are the first to directly compare the cardiovascular outcomes of these glucagon-like peptide 1 receptor agonist medications in a real-world setting. This study contributes to the understanding of the impact of these treatments on heart health in older populations at high risk.","news_type":1,"symbols_score_info":{"NVO":1.5}},"isVote":1,"tweetType":1,"viewCount":33,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":479904954815200,"gmtCreate":1758188456674,"gmtModify":1758189054969,"author":{"id":"4120588888192682","authorId":"4120588888192682","name":"Chidubem Thomas","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4120588888192682","authorIdStr":"4120588888192682"},"themes":[],"htmlText":"Thanks for contacting me ","listText":"Thanks for contacting me ","text":"Thanks for contacting me","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/479904954815200","repostId":"2568342652","repostType":2,"repost":{"id":"2568342652","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1758188259,"share":"https://ttm.financial/m/news/2568342652?lang=en_US&edition=fundamental","pubTime":"2025-09-18 17:37","market":"sh","language":"en","title":"Novo Nordisk Jumps 7% as Wegovy Pill Delivers 16.6% Weight Loss; Semaglutide Significantly Reduces Cardiovascular Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2568342652","media":"Dow Jones","summary":"Shares of $Novo Nordisk(NVO)$ continued to jump 7% in premarket trading.Novo's experimental daily Wegovy pill helped patients lose about as much weight as its weekly injection, according to data from...","content":"<html><head></head><body><p>Shares of <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> continued to jump 7% in premarket trading.</p><p>Novo's experimental daily Wegovy pill helped patients lose about as much weight as its weekly injection, according to data from a late-stage trial. Additionly, Novo Nordisk has announced the results of the REACH real-world study.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/be53cc818a2ab5a359d3e81ecb9ccbbd\" title=\"\" tg-width=\"840\" tg-height=\"621\"/></p><p>Results showed that if all patients adhered to treatment, they <strong>lost an average 16.6% of their weight,</strong> comparable with previous trial results of its once-weekly Wegovy jab, the company said late Wednesday.</p><p>The 64-week trial tested obese or overweight adults with a weight-related condition but without diabetes, and more than a third of those in the trial achieved weight loss of 20% or more, it said.</p><p>The study also found the pill improved cardiovascular risk factors, as well as the ability to be more active in daily life, while the safety and tolerability profile was consistent with the Wegovy jab.</p><p>Additionly, Novo Nordisk has announced the results of the REACH real-world study, which indicate that <strong>Ozempic (once-weekly injectable semaglutide) is associated with a 23% reduced risk of major adverse cardiovascular events, such as heart attack or stroke</strong>, compared to dulaglutide.</p><p>The study involved nearly 60,000 US Medicare patients aged 66 years or older with type 2 diabetes and atherosclerotic cardiovascular disease.</p><p>Additionally, Ozempic was linked to a 26% lower risk of death compared to dulaglutide. These findings, presented at the European Association for the Study of Diabetes (EASD) 2025 Annual Meeting in Vienna, Austria, are the first to directly compare the cardiovascular outcomes of these glucagon-like peptide 1 receptor agonist medications in a real-world setting. This study contributes to the understanding of the impact of these treatments on heart health in older populations at high risk.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk Jumps 7% as Wegovy Pill Delivers 16.6% Weight Loss; Semaglutide Significantly Reduces Cardiovascular Risk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk Jumps 7% as Wegovy Pill Delivers 16.6% Weight Loss; Semaglutide Significantly Reduces Cardiovascular Risk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-09-18 17:37</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Shares of <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> continued to jump 7% in premarket trading.</p><p>Novo's experimental daily Wegovy pill helped patients lose about as much weight as its weekly injection, according to data from a late-stage trial. Additionly, Novo Nordisk has announced the results of the REACH real-world study.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/be53cc818a2ab5a359d3e81ecb9ccbbd\" title=\"\" tg-width=\"840\" tg-height=\"621\"/></p><p>Results showed that if all patients adhered to treatment, they <strong>lost an average 16.6% of their weight,</strong> comparable with previous trial results of its once-weekly Wegovy jab, the company said late Wednesday.</p><p>The 64-week trial tested obese or overweight adults with a weight-related condition but without diabetes, and more than a third of those in the trial achieved weight loss of 20% or more, it said.</p><p>The study also found the pill improved cardiovascular risk factors, as well as the ability to be more active in daily life, while the safety and tolerability profile was consistent with the Wegovy jab.</p><p>Additionly, Novo Nordisk has announced the results of the REACH real-world study, which indicate that <strong>Ozempic (once-weekly injectable semaglutide) is associated with a 23% reduced risk of major adverse cardiovascular events, such as heart attack or stroke</strong>, compared to dulaglutide.</p><p>The study involved nearly 60,000 US Medicare patients aged 66 years or older with type 2 diabetes and atherosclerotic cardiovascular disease.</p><p>Additionally, Ozempic was linked to a 26% lower risk of death compared to dulaglutide. These findings, presented at the European Association for the Study of Diabetes (EASD) 2025 Annual Meeting in Vienna, Austria, are the first to directly compare the cardiovascular outcomes of these glucagon-like peptide 1 receptor agonist medications in a real-world setting. This study contributes to the understanding of the impact of these treatments on heart health in older populations at high risk.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4007":"制药","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4585":"ETF&股票定投概念","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4588":"碎股","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4599":"减肥药","NVO":"诺和诺德","BK4532":"文艺复兴科技持仓","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC"},"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2568342652","content_text":"Shares of Novo Nordisk continued to jump 7% in premarket trading.Novo's experimental daily Wegovy pill helped patients lose about as much weight as its weekly injection, according to data from a late-stage trial. Additionly, Novo Nordisk has announced the results of the REACH real-world study.Results showed that if all patients adhered to treatment, they lost an average 16.6% of their weight, comparable with previous trial results of its once-weekly Wegovy jab, the company said late Wednesday.The 64-week trial tested obese or overweight adults with a weight-related condition but without diabetes, and more than a third of those in the trial achieved weight loss of 20% or more, it said.The study also found the pill improved cardiovascular risk factors, as well as the ability to be more active in daily life, while the safety and tolerability profile was consistent with the Wegovy jab.Additionly, Novo Nordisk has announced the results of the REACH real-world study, which indicate that Ozempic (once-weekly injectable semaglutide) is associated with a 23% reduced risk of major adverse cardiovascular events, such as heart attack or stroke, compared to dulaglutide.The study involved nearly 60,000 US Medicare patients aged 66 years or older with type 2 diabetes and atherosclerotic cardiovascular disease.Additionally, Ozempic was linked to a 26% lower risk of death compared to dulaglutide. These findings, presented at the European Association for the Study of Diabetes (EASD) 2025 Annual Meeting in Vienna, Austria, are the first to directly compare the cardiovascular outcomes of these glucagon-like peptide 1 receptor agonist medications in a real-world setting. This study contributes to the understanding of the impact of these treatments on heart health in older populations at high risk.","news_type":1,"symbols_score_info":{"NVO":1.5}},"isVote":1,"tweetType":1,"viewCount":33,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
